北米の尿路感染症検査（UTI検査）の市場規模、シェア、動向分析レポート：タイプ別、製品別、最終用途別、国別、セグメント予測、2023年～2030年

北米の尿路感染症検査（UTI検査）市場の成長と動向：

Grand View Research, Inc.の新しい調査によると、北米のUTI検査市場規模は2030年までに2億6,916万米ドルに達する見込みです。

同市場は2023年から2030年にかけてCAGR 4.0％で拡大する見込みです。同地域のUTI検査市場は、同地域におけるUTI対策に関する政府のイニシアチブの増加、UTI検査の技術進歩、高度に発達した医療インフラ＆医療施設へのアクセスの改善によって成長しています。例えば、2019年7月にThe New York Timesが発表した記事によると、ニューヨーク市保健局は薬剤耐性UTIに対処するためのモバイルアプリを立ち上げました。このアプリは、医師や看護師に感染株のリストと特定の薬剤に対する耐性を提供します。

同省が実施した調査によると、最も一般的なタイプである大腸菌による尿路結石の多くは、バクトリムなどの広く使用されている薬剤に耐性があることが明らかになっています。薬剤耐性尿路結石に対するこのような懸念の高まりは、北米における高度なUTI検査ソリューションの需要を後押ししています。医療プロバイダーは、抗生物質耐性の増加という問題に立ち向かうため、より正確で的を絞った治療法を求めているからです。その結果、同地域のUTI検査市場は大きな成長を遂げています。

革新的な診断技術を取り入れることで、患者ケアと管理を大幅に強化することができる一方、より迅速な結果提供を通じて抗生物質スチュワードシップを促進することができるため、市場成長の原動力となっています。例えば、米国のエンジニアと分子生物学者のチームは、尿中の微生物病原体を迅速に検出する費用対効果の高いポイントオブケア診断テストを開発しました。シンプルな実験キット、LEDライト、ホットプレート、スマートフォンを使用するこの装置は、資源が限られた環境におけるUTIの迅速かつ低コストな診断に有望な可能性を示しています。

北米のUTI検査市場レポート・ハイライト

• 市場全体の成長は、同地域の人口におけるUTIの有病率の増加に起因しています。
• UTI検査市場は、技術的に先進的な在宅ケア用UTI検査キットに対する需要の高まりとともに重要な変化を迎えています。
• 膀胱炎は、患者における膀胱炎の高い発生率と再発率に起因して、2022年には41.41%の最大市場シェアを占めました。
• 機器部門は2022年に60.36%の売上シェアで市場を独占しました。これは、診断技術の進歩により、機能が強化された高度な機器が開発されたためです。
• 最終用途別では、リファレンスラボ分野が2022年に26.11%の最大売上シェアを占めました。これは、これらの検査室が提供する幅広い包括的検査サービスに起因します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 業界分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19感染症の影響分析

第4章 北米のUTI検査市場：タイプ分析

• 北米のUTI検査市場：タイプの変動分析
• 尿道炎
• 膀胱炎
• 腎盂腎炎

第5章 北米のUTI検査市場：製品分析

• 北米のUTI検査市場：製品の変動分析
• 機器
• 消耗品

第6章 北米のUTI検査市場：最終用途分析

• 北米のUTI検査市場：最終用途の変動分析
• 一般開業医
• 泌尿器科医
• 泌尿婦人科医
• 病院検査室
• リファレンスラボ
• 病院の救急部門
• 緊急処置
• その他

第7章 北米のUTI検査市場：地域分析

• 北米

第8章 競合情勢

• 参入企業
  • QIAGEN
  • Accelerate Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.
  • bioMerieux SA
  • T2 Biosystems, Inc.
• 参入企業の概要
• 財務実績
• 製品のベンチマーク
• 企業の市場シェア分析、2022年
• 戦略マッピング
  • 拡張
  • 買収
  • 製品/サービスの発売
  • その他

第9章 結論/アナリストの視点

List of Tables

• 1. List of Secondary Sources
• 2. List of Abbreviations
• 3. North America Urinary Tract Infection Testing Market, By Country, 2018 - 2030 (USD Million)
• 4. North America Urinary Tract Infection Testing Market, By Type, 2018 - 2030 (USD Million)
• 5. North America Urinary Tract Infection Testing Market, By Product, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 6. North America Urinary Tract Infection Testing Market, by End - use, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 7. U.S. Urinary Tract Infection Testing Market, by Type, 2018 - 2030 (USD Million)
• 8. U.S. Urinary Tract Infection Testing Market, By Product, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 9. U.S. Urinary Tract Infection Testing Market, by End - use, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 10. Canada Urinary Tract Infection Testing Market, by Type, 2018 - 2030 (USD Million)
• 11. Canada Urinary Tract Infection Testing Market, By Product, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 12. Canada Urinary Tract Infection Testing Market, by End - use, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)

List of Figures

• 1. Market research process
• 2. Information procurement
• 3. Primary research pattern
• 4. Market research approaches
• 5. Value chain - based sizing & forecasting
• 6. Market formulation & validation
• 7. North America urinary tract infection testing: Market segmentation
• 8. Market snapshot, 2022
• 9. Market Trends & Outlook
• 10. Market driver relevance analysis (current & future impact)
• 11. Market restraint relevance analysis (current & future impact)
• 12. Market challenge relevance analysis (current & future impact)
• 13. SWOT analysis
• 14. Porter's five forces analysis
• 15. North America urinary tract infection testing market: Type outlook and key takeaways
• 16. North America urinary tract infection testing market: Type movement analysis & market share, 2022 & 2030
• 17. Urethritis market estimates and forecast, 2018 - 2030 (USD Million)
• 18. Cystitis market estimates and forecast, 2018 - 2030 (USD Million)
• 19. Pyelonephritis market estimates and forecast, 2018 - 2030 (USD Million)
• 20. North America urinary tract infection testing market: Product outlook and key takeaways
• 21. North America urinary tract infection testing market: Product movement analysis & market share, 2022 & 2030
• 22. Instruments market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 23. Consumables market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 24. North America urinary tract infection testing market: End - use outlook and key takeaways
• 25. North America urinary tract infection testing market: End - use movement analysis & market share, 2022 & 2030
• 26. General practitioners market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 27. Urologists market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 28. Urogynecologists market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 29. Hospital laboratories market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 30. Reference laboratories market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 31. Hospital emergency departments market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 32. Urgent care market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 33. Others market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 34. Regional marketplace: key takeaways
• 35. Regional outlook, 2022 & 2030
• 36. North America urinary tract infection testing market: region movement analysis.
• 37. North America urinary tract infection testing market, 2018 - 2030 (Revenue, USD Million, 2018 - 2030)
• 38. U.S. key country dynamics
• 39. U.S. urinary tract infection testing market, 2018 - 2030 (Revenue, USD Million, 2018 - 2030)
• 40. Canada key country dynamics
• 41. Canada urinary tract infection testing market, 2018 - 2030 (Revenue, USD Million, 2018 - 2030)

North America Urinary Tract Infection Testing Market Growth & Trends:

The North America urinary tract infection testing market size is expected to reach USD 269.16 million by 2030, according to a new study by Grand View Research, Inc.. The market is expected to expand at a CAGR of 4.0% from 2023 to 2030. The regional UTI testing market is growing due to increasing government initiatives regarding UTI control in the region, technological advancements in UTI testing, and highly developed healthcare infrastructure & improved access to healthcare facilities. For instance, an article published by The New York Times in July 2019 mentioned that the New York City Department of Health launched a mobile app to address drug-resistant urinary tract infections (UTIs). The app provides doctors and nurses with a list of infection strains and their resistance to specific drugs.

Research conducted by this department revealed that many of the UTIs caused by E. coli, the most common type, were resistant to widely used drugs like Bactrim. This growing concern over drug-resistant UTIs drives the demand for advanced UTI testing solutions in North America, as healthcare providers seek more accurate and targeted therapies to combat the rising issue of antibiotic resistance. As a result, the UTI testing market in the region is experiencing significant growth.

Incorporating innovative diagnostic technologies can significantly enhance patient care and management while promoting antibiotic stewardship through faster result delivery, thereby driving market growth. For instance, a team of engineers and molecular biologists in the U.S. has developed a cost-effective point-of-care diagnostic test for rapidly detecting microbial pathogens in urine. Using a simple lab kit, LED lights, a hot plate, and a smartphone, the device shows promising potential for quick and low-cost diagnosis of urinary tract infections (UTIs) in resource-limited settings.

Furthermore, a pilot study published in eBioMedicine compared the smartphone-based real-time loop-mediated isothermal amplification (smaRT-LAMP) system to the more expensive rapid diagnostic technologies and standard hospital tests. The results demonstrated that the smaRT-LAMP system matched the accuracy of hospital diagnostics while significantly reducing costs and testing time.

Key players in the regional urinary tract infection testing market, such as F. Hoffmann-La Roche Ltd., bioMerieux SA, T2 Biosystems, Abbott, Siemens Healthcare GmbH, etc., are implementing strategic initiatives such as mergers, acquisitions, and collaborations to enhance product capabilities and promote their offerings. For instance, in November 2022, Illumina, a global leader in DNA sequencing and array-based technologies, introduced the Illumina Urinary Pathogen Infectious Disease/Antimicrobial Resistance (ID/AMR) Panel (UPIP). This research test utilizes precision metagenomics to identify and measure genitourinary pathogens, including drug-resistant ones that lead to complicated and recurrent urinary tract infections (UTIs).

North America Urinary Tract Infection Testing Market Report Highlights:

• The growth of the overall market is attributed to the increasing prevalence of UTIs among the population in the region
• The UTI testing market is witnessing a key shift with the rise in demand for technologically advanced homecare UTI testing kits
• Cystitis held the largest market share of 41.41% in 2022, owing to the high incidence & recurrence rate of cystitis in patients
• The instruments segment dominated the market with a revenue share of 60.36% in 2022. This is attributed to advancements in diagnostic technologies that have led to the development of sophisticated instruments with enhanced capabilities
• Based on end-use, the reference laboratories segment accounted for the largest revenue share of 26.11% in 2022. This is attributed to the wide range of comprehensive testing services offered by these laboratories

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Type segment
    • 1.1.1.2. Product segment
    • 1.1.1.3. End-user segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Product and Type Snapshot
• 2.3. End-use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of urinary tract infections (UTIs)
    • 3.2.1.2. Technological Advancements in Urinary Tract Infection Testing
    • 3.2.1.3. Growing prevalence of catheter-associated UTIs (CAUTIs)
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost associated with advanced UTI testing technologies.
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. North America Urinary Tract Infection Testing Market: Type Analysis

• 4.1. North America Urinary Tract Infection Testing Market: Type Movement Analysis
• 4.2. Urethritis
  • 4.2.1. Urethritis Market, 2018 - 2030 (USD Million)
• 4.3. Cystitis
  • 4.3.1. Cystitis Market, 2018 - 2030 (USD Million)
• 4.4. Pyelonephritis
  • 4.4.1. Pyelonephritis Market, 2018 - 2030 (USD Million)

Chapter 5. North America Urinary Tract Infection Testing Market: Product Analysis

• 5.1. North America Urinary Tract Infection Testing Market: Product Movement Analysis
• 5.2. Instruments
  • 5.2.1. Instruments Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 5.3. Consumables
  • 5.3.1. Consumables Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)

Chapter 6. North America Urinary Tract Infection Testing Market: End-use Analysis

• 6.1. North America Urinary Tract Infection Testing Market: End-use Movement Analysis
• 6.2. General Practitioners
  • 6.2.1. General Practitioners Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 6.3. Urologists
  • 6.3.1. Urologists Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 6.4. Urogynecologists
  • 6.4.1. Urogynecologists Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 6.5. Hospital Laboratories
  • 6.5.1. Hospital Laboratories Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 6.6. Reference Laboratories
  • 6.6.1. Reference Laboratories Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 6.7. Hospital Emergency Departments
  • 6.7.1. Hospital Emergency Departments Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 6.8. Urgent Care
  • 6.8.1. Urgent Care Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
• 6.9. Others
  • 6.9.1. Others Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)

Chapter 7. North America Urinary Tract Infection Testing Market: Regional Analysis

• 7.1. North America
  • 7.1.1. SWOT Analysis
  • 7.1.2. North America Urinary Tract Infection Testing Market, 2018 - 2030 (USD Million)
  • 7.1.3. U.S.
    • 7.1.3.1. Key Country Dynamics
    • 7.1.3.2. Target Disease Prevalence
    • 7.1.3.3. Competitive Scenario
    • 7.1.3.4. Regulatory Framework
    • 7.1.3.5. U.S. Urinary Tract Infection Testing Market, 2018 - 2030 (USD Million)
  • 7.1.4. Canada
    • 7.1.4.1. Key Country Dynamics
    • 7.1.4.2. Target Disease Prevalence
    • 7.1.4.3. Competitive Scenario
    • 7.1.4.4. Regulatory Framework
    • 7.1.4.5. Canada Urinary Tract Infection Testing Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
  • 8.1.1. QIAGEN
    • 8.1.1.1. Overview
    • 8.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.1.1.3. Product Benchmarking
    • 8.1.1.4. Strategic Initiatives
  • 8.1.2. Accelerate Diagnostics, Inc.
    • 8.1.2.1. Overview
    • 8.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.1.2.3. Product Benchmarking
    • 8.1.2.4. Strategic Initiatives
  • 8.1.3. Bio-Rad Laboratories, Inc.
    • 8.1.3.1. Overview
    • 8.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.1.3.3. Product Benchmarking
    • 8.1.3.4. Strategic Initiatives
  • 8.1.4. F. Hoffmann-La Roche Ltd.
    • 8.1.4.1. Overview
    • 8.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.1.4.3. Product Benchmarking
    • 8.1.4.4. Strategic Initiatives
  • 8.1.5. Danaher Corporation
    • 8.1.5.1. Overview
    • 8.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.1.5.3. Product Benchmarking
    • 8.1.5.4. Strategic Initiatives
  • 8.1.6. Siemens Healthcare GmbH
    • 8.1.6.1. Overview
    • 8.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.1.6.3. Product Benchmarking
    • 8.1.6.4. Strategic Initiatives
  • 8.1.7. Randox Laboratories Ltd.
    • 8.1.7.1. Overview
    • 8.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.1.7.3. Product Benchmarking
    • 8.1.7.4. Strategic Initiatives
  • 8.1.8. Thermo Fisher Scientific, Inc.
    • 8.1.8.1. Overview
    • 8.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.1.8.3. Product Benchmarking
    • 8.1.8.4. Strategic Initiatives
  • 8.1.9. bioMerieux SA
    • 8.1.9.1. Overview
    • 8.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.1.9.3. Product Benchmarking
    • 8.1.9.4. Strategic Initiatives
  • 8.1.10. T2 Biosystems, Inc.
    • 8.1.10.1. Overview
    • 8.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.1.10.3. Product Benchmarking
    • 8.1.10.4. Strategic Initiatives
• 8.2. Participant's Overview
• 8.3. Financial Performance
• 8.4. Product Benchmarking
• 8.5. Company Market Share Analysis, 2022
• 8.6. Strategy Mapping
  • 8.6.1. Expansions
  • 8.6.2. Acquisitions
  • 8.6.3. Product/Service Launches
  • 8.6.4. Others

Chapter 9. Conclusion/Analyst Perspective